Pneumonitis Risk in NSCLC Remains Uncertain, Obesity May Be

Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.

Related Keywords

United States , , Thoracic Disease , Computing Infrastructure , Nsclc , Obesity , Durvalumab ,